RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000069.xml
PDF herunterladen
Semin Liver Dis 2003; 23(3): 283-294
DOI: 10.1055/s-2003-42646
DOI: 10.1055/s-2003-42646
New Liver Support Devices in Acute Liver Failure: A Critical Evaluation
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
02. Oktober 2003 (online)
ABSTRACT
Acute liver failure remains a condition with substantial mortality in spite of the best available medical care. Liver transplantation is often not possible or delayed, and liver support systems can be used to maintain the patient during the crisis by bridging to transplantation or allowing recovery of the native liver. Bioartificial devices, using porcine or human hepatocytes, have yielded encouraging results on consciousness levels in a number of studies and have generally been found to be safe, although in one large controlled trial reported to date, benefit was restricted to certain subgroups. Artificial devices, like those based on albumin dialysis, are undoubtedly effective in removing protein-bound toxins, and uncontrolled evidence shows some survival benefit. The large multicenter controlled trials necessary for proving the value of these systems are difficult to design. They have to take into account the influence of transplantation, etiology, and other factors on outcome. Achieving a standard medical regime for these critically ill patients between different centers is also difficult.
KEYWORDS
Extracorporeal - bioartificial - hepatocytes - albumin dialysis
REFERENCES
- 1 Stockmann H B, IJzermans J N. Prospects for the temporary treatment of acute liver failure. Eur J Gastroenterol Hepatol . 2002; 14 195-203
- 2 Miwa S, Hashikura Y, Mita A. et al . Living-related liver transplantation for patients with fulminant and subfulminant hepatic failure. Hepatology . 1999; 30 1521-1526
- 3 Baker A, Dhawan A, Devlin J. et al . Assessment of potential donors for living related liver transplantation. Br J Surg . 1999; 86 200-205
- 4 Abouna G M. Cross-circulation between man and baboon in hepatic coma. Lancet . 1968; 2 729-730
- 5 Motin J, Bouletreau P, Petit P, Latarjet J. Hepatic assistance by means of inter-human cross circulation. Apropos of 6 cases. Minerva Chir . 1974; 29 989-993
- 6 Abouna G M, Garry R, Hull C. et al . Pig-liver perfusion in hepatic coma. Lancet . 1968; 2 509-510
- 7 Ranek L, Hansen R I, Hilden M. et al . Pig liver perfusion in the treatment of acute hepatic failure. Scand J Gastroenterol Suppl . 1971; 9 161-169
- 8 Graw Jr G R, Buckner C D, Eisel R. Plasma exchange transfusion for hepatic coma. New technic. Transfusion . 1970; 10 26-32
- 9 Larsen F S, Hansen B A, Jorgensen L G. et al . High-volume plasmapheresis and acute liver transplantation in fulminant hepatic failure. Transplant Proc . 1994; 26 1788
- 10 Clemmesen J O, Kondrup J, Nielsen L B. et al . Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure. Am J Gastroenterol . 2001; 96 1217-1223
- 11 Clemmesen J O, Larsen F S, Ejlersen E. et al . Haemodynamic changes after high-volume plasmapheresis in patients with chronic and acute liver failure. Eur J Gastroenterol Hepatol . 1997; 9 55-60
- 12 Larsen F S, Hansen B A, Ejlersen E. et al . Cerebral blood flow, oxygen metabolism and transcranial Doppler sonography during high-volume plasmapheresis in fulminant hepatic failure. Eur J Gastroenterol Hepatol . 1996; 8 261-265
- 13 O'Grady J G, Gimson A E, O'Brien C J. et al . Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology . 1988; 94 1186-1192
- 14 McGuire B M, Sielaff T D, Nyberg S L. et al . Review of support systems used in the management of fulminant hepatic failure. Dig Dis . 1995; 13 379-388
- 15 Allen J W, Hassanein T, Bhatia S N. Advances in bioartificial liver devices. Hepatology . 2001; 34 447-455
- 16 Jauregui H O, Mullon C J, Trenkler D. et al . In vivo evaluation of a hollow fiber liver assist device. Hepatology . 1995; 21 460-469
- 17 Nyberg S L, Peshwa M V, Payne W D. et al . Evolution of the bioartificial liver: the need for randomized clinical trials. Am J Surg . 1993; 166 512-521
- 18 Sussman N L, Chong M G, Koussayer T. et al . Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology . 1992; 16 60-65
- 19 Rozga J, Williams F, Ro M S. et al . Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology . 1993; 17 258-265
- 20 Flendrig L M, Calise F, Di Florio E. et al . Significantly improved survival time in pigs with complete liver ischemia treated with a novel bioartificial liver. Int J Artif Organs . 1999; 22 701-709
- 21 Sosef M N, Abrahamse L S, van de Kerkhove P M. et al . Assessment of the AMC-bioartificial liver in the anhepatic pig. Transplantation . 2002; 73 204-209
- 22 Arai K, Lee K, Berthiaume F. et al . Intrahepatic amino acid and glucose metabolism in a D-galactosamine-induced rat liver failure model. Hepatology . 2001; 34 360-371
- 23 Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver . 2002; 22(Suppl 2) 5-13
- 24 Hughes R D, Cochrane A M, Thomson A D. et al . The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. Br J Exp Pathol . 1976; 57 348-353
- 25 Suh K S, Lilja H, Kamohara Y. et al . Bioartificial liver treatment in rats with fulminant hepatic failure: effect on DNA-binding activity of liver-enriched and growth-associated transcription factors. J Surg Res . 1999; 85 243-250
- 26 Strain A J, Neuberger J M. A bioartificial liver-state of the art. Science . 2002; 295 1005-1009
- 27 Nagasue N, Yukaya H, Ogawa Y. et al . Human liver regeneration after major hepatic resection. A study of normal liver and livers with chronic hepatitis and cirrhosis. Ann Surg . 1987; 206 30-39
- 28 Arkadopoulos N, Lilja H, Suh K S. et al . Intrasplenic transplantation of allogeneic hepatocytes prolongs survival in anhepatic rats. Hepatology . 1998; 28 1365-1370
- 29 Wu L, Sun J, Wang L. et al . Cryopreservation of primary porcine hepatocytes for use in bioartificial liver support systems. Transplant Proc . 2000; 32 2271-2272
- 30 Yagi T, Hardin J A, Valenzuela Y M. et al . Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes. Hepatology . 2001; 33 1432-1440
- 31 Kono Y, Yang S, Letarte M, Roberts E A. Establishment of a human hepatocyte line derived from primary culture in a collagen gel sandwich culture system. Exp Cell Res . 1995; 221 478-485
- 32 McCloskey P, Edwards R J, Tootle R. et al . Resistance of three immortalized human hepatocyte cell lines to acetaminophen and N-acetyl-p-benzoquinoneimine toxicity. J Hepatol . 1999; 31 841-81
- 33 McCloskey P, Tootle R, Selden C. et al . Modulation of hepatocyte function in an immortalized human hepatocyte cell line following exposure to liver-failure plasma. Artif Organs . 2002; 26 340-348
- 34 Gerlach J C, Schnoy N, Encke J. et al . Improved hepatocyte in vitro maintenance in a culture model with woven multicompartment capillary systems: electron microscopy studies. Hepatology . 1995; 22 546-552
- 35 Flendrig L M, la Soe W J, Jorning G G. et al . In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates. J Hepatol . 1997; 26 1379-1392
- 36 Morsiani E, Pazzi P, Puviani A C. et al . Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. Int J Artif Organs . 2002; 25 192-202
- 37 Riordan S M, Williams R. Acute liver failure: targeted artificial and hepatocyte-based support of liver regeneration and reversal of multiorgan failure. J Hepatol . 2000; 32(Suppl 1) 63-76
- 38 Matsumura K N, Guevara G R, Huston H. et al . Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery . 1987; 101 99-103
- 39 Chen S C, Hewitt W R, Watanabe F D. et al . Clinical experience with a porcine hepatocyte-based liver support system. Int J Artif Organs . 1996; 19 664-669
- 40 Watanabe F D, Mullon C J, Hewitt W R. et al . Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg . 1997; 225 484-491
- 41 Samuel D, Ichai P, Feray C. et al . Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation . 2002; 73 257-264
- 42 Stevens A C, Busuttil R, Han S. et al . An interim analysis of a phase II/III prospective randomized, multicenter, controlled trial of the Hepatassist(R) bioartificial liver support system for the treatment of fulminant hepatic failure (Abst). Hepatology . 2001; 34 299A
- 43 Ellis A J, Hughes R D, Wendon J A. et al . Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology . 1996; 24 1446-1451
- 44 Millis J M, Kramer D J, O'Grady J. et al . Results of phase I trial of the extracorporeal liver assist device for patients with fulminant hepatic failure. Am J Transplantation . 2001; 1(Suppl 1) 391
- 45 van de Kerkhove P M, Di Florio E, Scuderi V. et al . Phase I clinical trial with the AMC-bioartificial liver. Academic Medical Center. Int J Artif Organs . 2002; 25 950-959
- 46 Sauer I M, Zeilinger K, Obermayer N. et al . Primary human liver cells as source for modular extracorporeal liver support-a preliminary report. Int J Artif Organs . 2002; 25 1001-1005
- 47 Mundt A, Puhl G, Muller A. et al . A method to assess biochemical activity of liver cells during clinical application of extracorporeal hybrid liver support. Int J Artif Organs . 2002; 25 542-548
- 48 Sauer I M, Kardassis D, Zeillinger K. et al . Clinical extracorporeal hybrid liver support-phase I study with primary porcine liver cells (in press). Xenotransplantation . 2003;
- 49 Jalan R, Williams R. Bio-artificial liver support for acute liver failure: should we be using it to treat patients?. Transplantation . 2002; 73 165-166
- 50 Baquerizo A, Mhoyan A, Shirwan H. et al . Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver. Transplant Proc . 1997; 29 964-965
- 51 Abouna G M, Boehmig H G, Serrou B. et al . Long-term hepatic support by intermittent multi-species liver perfusions. Lancet . 1970; 2 391-396
- 52 Nyberg S L, Hibbs J R, Hardin J A. et al . Influence of human fulminant hepatic failure sera on endogenous retroviral expression in pig hepatocytes. Liver Transpl . 2000; 6 76-84
- 53 Patience C, Takeuchi Y, Weiss R A. Infection of human cells by an endogenous retrovirus of pigs. Nat Med . 1997; 3 282-286
- 54 Martin U, Kiessig V, Blusch J H. et al . Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells. Lancet . 1998; 352 692-694
- 55 Wilson C A, Wong S, Muller J. et al . Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cells. J Virol . 1998; 72 3082-3087
- 56 Nyberg S L, Hibbs J R, Hardin J A. et al . Transfer of porcine endogenous retrovirus across hollow fiber membranes: significance to a bioartificial liver. Transplantation . 1999; 67 1251-1255
- 57 Martin U, Winkler M E, Id M. et al . Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV). Xenotransplantation . 2000; 7 138-142
- 58 Heneine W, Tibell A, Switzer W M. et al . No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet . 1998; 352 695-699
- 59 Paradis K, Langford G, Long Z. et al . Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science . 1999; 285 1236-1241
- 60 Patience C, Patton G S, Takeuchi Y. et al . No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet . 1998; 352 699-701
- 61 Mitzner S R, Stange J, Klammt S. et al . Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol . 2001; 12(Suppl 17) S75-S82
- 62 Stange J, Ramlow W, Mitzner S. et al . Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs . 1993; 17 809-813
- 63 Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Int J Artif Organs . 1996; 19 677-691
- 64 Hughes R, Ton H Y, Langley P. et al . Albumin-coated Amberlite XAD-7 resin for hemoperfusion in acute liver failure. Part II: in vivo evaluation. Artif Organs . 1979; 3 23-26
- 65 Stange J, Mitzner S, Ramlow W. et al . A new procedure for the removal of protein bound drugs and toxins. Asaio J . 1993; 39 M621-625
- 66 Ash S R, Blake D E, Carr D J. et al . Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Int J Artif Organs . 1992; 15 151-161
- 67 Ash S R, Blake D E, Carr D J, Harker K D. Push-pull sorbent based pheresis for treatment of acute hepatic failure: the BioLogic-detoxifier/plasma filter System. Asaio J . 1998; 44 129-139
- 68 Hughes R D, Pucknell A, Routley D. et al . Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs . 1994; 17 657-662
- 69 Mitzner S R, Klammt S, Peszynski P. et al . Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher . 2001; 5 417-422
- 70 Sorkine P, Ben Abraham R, Szold O. et al . Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med . 2001; 29 1332-1336
- 71 Stange J, Mitzner S R, Risler T. et al . Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs . 1999; 23 319-330
- 72 Mitzner S R, Stange J, Klammt S. et al . Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl . 2000; 6 277-286
- 73 Heemann U, Treichel U, Loock J. et al . Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology . 2002; 36 949-958
- 74 Novelli G, Rossi M, Pretagostini R. et al . MARS (Molecular Adsorbent Recirculating System): experience in 34 cases of acute liver failure. Liver . 2002; 22(Suppl 2) 43-47
- 75 Isoniemi H. Current indications for albumin dialysis: acute hepatic failure. In: 4th International Symposium on Albumin Dialysis in Liver Disease Rostock-Warnemunde, Germany: University of Rostock; September 6-8 2002: 21-22
MissingFormLabel
- 76 Abraham R B, Szold O, Merhav H. et al . Rapid resolution of brain edema and improved cerebral perfusion pressure following the molecular adsorbent recycling system in acute liver failure patients. Transplant Proc . 2001; 33 2897-2899
- 77 Awad S S, Swaniker F, Magee J. et al . Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery . 2001; 130 354-362
- 78 Lamesch P, Jost U, Schreiter D. et al . Molecular adsorbant recirculating system in patients with liver failure. Transplant Proc . 2001; 33 3480-482
- 79 Manz T, Bisse E, Ochs A. et al . MARS for treatment of fulminant Wilson crisis. Z Gastroenterol . 2001; 39(Suppl) 49
- 80 Sen S, Felldin M, Steiner C. et al . Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease. Liver Transplantation . 2002; 8 962-967
- 81 Kreymann B, Seige M, Schweigart U. et al . Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins. J Hepatol . 1999; 31 1080-1085
- 82 McIntyre C W, Fluck R J, Freeman J G, Lambie S H. Use of albumin dialysis in the treatment of hepatic and renal dysfunction due to paracetamol intoxication. Nephrol Dial Transplant . 2002; 17 316-317
- 83 Siewert-Delle A, Henriksson B A, Baeckmann L. Albumin dialysis with the MARS for a patient with acute liver failure due to paracetamol intoxication: a case report. Z Gastroenterol . 2001; 39(Suppl) 48
- 84 Shi Y, He J, Chen S. et al . MARS: optimistic therapy method in fulminant hepatic failure secondary to cytotoxic mushroom poisoning-a case report. Liver . 2002; 22(Suppl 2) 78-80
- 85 Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver . 2002; 22(Suppl 2) 20-25
- 86 Mallet V O, Mitchell C, Mezey E. et al . Bone marrow transplantation in mice leads to a minor population of hepatocytes that can be selectively amplified in vivo. Hepatology . 2002; 35 799-804
- 87 Kobayashi N, Fujiwara T, Westerman K A. et al . Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science . 2000; 287 1258-1262
- 88 Seternes T, Sorensen K, Smedsrod B. Scavenger endothelial cells of vertebrates: a nonperipheral leukocyte system for high-capacity elimination of waste macromolecules. Proc Natl Acad Sci USA . 2002; 99 7594-7597
- 89 Auth M K, Joplin R E, Okamoto M. et al . Morphogenesis of primary human biliary epithelial cells: induction in high-density culture or by coculture with autologous human hepatocytes. Hepatology . 2001; 33 519-529
- 90 Sirica A E, Gainey T W. A new rat bile ductular epithelial cell culture model characterized by the appearance of polarized bile ducts in vitro. Hepatology . 1997; 26 537-549